| Company Name: | Parexel International Corporation | | Ticker Symbol: | PRXL | | | WWW Address: | www.parexel.com | | CEO: | Josef H. von Rickenbach | | No. of Employees: | 9,275 | | Common Issue Type: | CS | | Business Description: | A biopharmaceutical company, providing expertise in clinical research, medical communications services, consulting, and informatics and advanced technology products and services to the pharmaceutical, biotechnology, and medical device industries.
|
| | | Industry Information: | DIVERSIFIED SERVICES - Research Services [more like this] |
|
| Price | Day Change | Bid | Ask | Open | High | Low | Volume | | 12.87 |  -0.01 | 12.24 | 13.6 | 12.85 | 13.00 | 12.69 | 201922 |
| Market Cap (mil) | Shares Outstanding (mil) | Beta | EPS | DPS | P/E | Yield | 52-Wks-Range |
| 749.0 | 58.2 | 1.20 | 0.68 | 0.00 | 19.5 | 0.0 | 16.62 - 6.80 |
|
| KEY FIGURES (Latest Twelve Months - LTM) | | Yesterday's Close | 12.87 | $ | | PE Ratio - LTM | 19.5 | |
| Market Capitalisation | 748.4 | mil |
| Latest Shares Outstanding | 58.2 | mil |
| Earnings pS (EPS) | 0.68 | $ |
| Dividend pS (DPS) | 0.00 | ¢ |
| Dividend Yield | 0.0 | % |
| Dividend Payout Ratio | 0 | % |
| Revenue per Employee | 134,435 | $ |
| Effective Tax Rate | 37.9 | % |
| Float | 49.1 | mil |
| Float as % of Shares Outstanding | 84.2 | % |
| Foreign Sales | 624 | mil |
| Domestic Sales | 622 | mil |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 18.60 | % |
| Research & Devlopment (R&D) as % of Revenue | 0.00 | % |
| Gross Profit Margin | 30.1 | % |
| EBITDA Margin | 11.5 | % |
| Pre-Tax Profit Margin | 5.2 | % |
| Assets Turnover | 1.1 | % |
| Return on Assets (ROA) | 3.2 | % |
| Return on Equity (ROE) | 9.5 | % |
| Return on Capital Invested (ROCI) | 5.9 | % |
| Current Ratio | 1.4 | |
| Leverage Ratio (Assets/Equity) | 3.0 | |
| Interest Cover | 3.7 | |
| Total Debt/Equity (Gearing Ratio) | 0.67 | |
| LT Debt/Total Capital | 37.0 | % |
| Working Capital pS | 3.30 | $ |
| Cash pS | 1.66 | $ |
| Book-Value pS | 7.13 | $ |
| Tangible Book-Value pS | 1.18 | $ |
| Cash Flow pS | 1.59 | $ |
| Free Cash Flow pS | -2.67 | $ |
 |
| KEY FIGURES (LTM): Price info |
| Price/Book Ratio | 1.80 | |
| Price/Tangible Book Ratio | 10.95 | |
| Price/Cash Flow | 8.1 | |
| Price/Free Cash Flow | -4.8 | |
| P/E as % of Industry Group | 43.0 | % |
| P/E as % of Sector Segment | 9.0 | % |
| | | Balance Sheet (at a glance) in Millions |
| | | | | | DIVIDEND INFO | | Type of Payment | - |
| Dividend Rate | 0.00 |
| Current Dividend Yield | 0.0 |
| 5-Y Average Dividend Yield | 0.0 |
| Payout Ratio | 0.0 |
| 5-Y Average Payout Ratio | 0.0 |
| |
| |
| |
| |
| |
|  | | Share price performance previous 3 years |
|
 | | | Share price performance intraday |
|
 | |
| |
| PRICE/VOLUME | High | Low | Close | % Price Chg | % Price Chg vs. Mkt. | Avg. Daily Vol | Total Vol |
| 1 Week | - | - | - | 2.5 | 101 | 2,898 | 4,364 |
| 4 Weeks | 13.71 | 11.78 | 12.52 | 2.8 | 96 | 3,811 | 64,779 |
| 13 Weeks | 14.83 | 11.78 | 13.06 | -1.5 | 92 | 4,620 | 281,819 |
| 26 Weeks | 16.62 | 10.45 | 10.44 | 23.3 | 102 | 5,753 | 719,077 |
| 52 Weeks | 16.62 | 6.80 | 8.32 | 54.7 | 125 | 6,961 | 1,733,201 |
| YTD | 16.62 | 7.20 | - | 32.5 | 108 | 6,894 | 1,565,013 |
| Moving Average | 5-Days | 10-Days | 10-Weeks | 30-Weeks | 200-Days | Beta (60-Mnth) | Beta (36-Mnth) |
| 12.78 | 12.80 | 13.17 | 12.95 | 12.05 | 1.20 | 1.32 |
|
| |
| GROWTH RATES | 5-Year
Growh | R² of 5-Year Growth | 3-Year
Growth |
| Revenue | 14.88 | 94.0 | 14.91 |
| Income | 0.00 | 0.0 | 9.62 |
| Dividend | 0.00 | 0.0 | 0.00 |
| Capital Spending | 50.54 | NA | 82.02 |
| R&D | 0.00 | NA | 0.00 |
| Normalized Inc. | 0.00 | NA | 20.83 |
| | | CHANGES | YTD vs.
Last YTD | Curr Qtr vs.
Qtr 1-Yr ago | Annual vs.
Last Annual |
| Revenue % | -3.8 | -3.8 | 7.2 |
| Earnings % | -8.6 | -8.6 | -39.2 |
| EPS % | -8.7 | -8.7 | -39.3 |
| EPS $ | -0.02 | -0.02 | -0.44 |
|
| |
| SOLVENCY RATIOS | | SHORT-TERM SOLVENCY RATIOS (LIQUIDITY) |
| Net Working Capital Ratio | 15.66 |
| Current Ratio | 1.4 |
| Quick Ratio (Acid Test) | 1.3 |
| Liquidity Ratio (Cash) | 0.21 |
| Receivables Turnover | 2.6 |
| Average Collection Period | 138 |
| Working Capital/Equity | 46.2 |
| Working Capital pS | 3.32 |
| Cash-Flow pS | 1.60 |
| Free Cash-Flow pS | -2.69 |
| FINANCIAL STRUCTURE RATIOS |
| Altman's Z-Score Ratio | 2.03 |
| Financial Leverage Ratio (Assets/Equity) | 3.0 |
| Debt Ratio | 66.1 |
| Total Debt/Equity (Gearing Ratio) | 0.67 |
| LT Debt/Equity | 0.60 |
| LT Debt/Capital Invested | 53.5 |
| LT Debt/Total Liabilities | 30.5 |
| Interest Cover | 3.7 |
| Interest/Capital Invested | 3.12 |
| | | | VALUATION RATIOS | | MULTIPLES |
| PQ Ratio | 6.62 |
| Tobin's Q Ratio | 0.61 |
| Current P/E Ratio - LTM | 19.50 |
| Enterprise Value (EV)/EBITDA | 10.18 |
| Enterprise Value (EV)/Free Cash Flow | -12.23 |
| Dividend Yield | 0.0 |
| Price/Tangible Book Ratio - LTM | 10.95 |
| Price/Book Ratio - LTM | 1.80 |
| Price/Cash Flow Ratio | 8.1 |
| Price/Free Cash Flow Ratio - LTM | -4.8 |
| Price/Sales Ratio | 0.61 |
| P/E Ratio (1 month ago) - LTM | 21.6 |
| P/E Ratio (26 weeks ago) - LTM | 10.4 |
| P/E Ratio (52 weeks ago) - LTM | 7.5 |
| 5-Y High P/E Ratio | 0.0 |
| 5-Y Low P/E Ratio | 0.0 |
| 5-Y Average P/E Ratio | 0.0 |
| Current P/E Ratio as % of 5-Y Average P/E | 0 |
| P/E as % of Industry Group | 43.0 |
| P/E as % of Sector Segment | 9.0 |
| Current 12 Month Normalized P/E Ratio - LTM | 18.9 |
| PER SHARE FIGURES |
| LT Debt pS | 4.28 |
| Current Liabilities pS | 7.89 |
| Tangible Book Value pS - LTM | 1.18 |
| Book Value pS - LTM | 7.13 |
| Capital Invested pS | 11.38 |
| Cash pS - LTM | 1.66 |
| Cash Flow pS - LTM | 1.59 |
| Free Cash Flow pS - LTM | -2.67 |
| Earnings pS (EPS) | 0.68 |
| | | | OPERATING RATIOS | | PROFITABILITY RATIOS |
| Free Cash Flow Margin | -12.46 |
| Free Cash Flow Margin 5YEAR AVG | -5.55 |
| Net Profit Margin | 3.2 |
| Net Profit Margin - 5YEAR AVRG. | 2.7 |
| Equity Productivity | 3.01 |
| Return on Equity (ROE) | 9.5 |
| Return on Equity (ROE) - 5YEAR AVRG. | 8.0 |
| Capital Invested Productivity | 1.88 |
| Return on Capital Invested (ROCI) | 5.9 |
| Return on Capital Invested (ROCI) - 5YEAR AVRG. | 6.9 |
| Assets Productivity | 1.10 |
| Return on Assets (ROA) | 3.2 |
| Return on Assets (ROA) - 5YEAR AVRG. | 3.4 |
| Gross Profit Margin | 30.1 |
| Gross Profit Margin - 5YEAR AVRG. | 28.5 |
| EBITDA Margin - LTM | 11.5 |
| EBIT Margin - LTM | 7.1 |
| Pre-Tax Profit Margin | 5.2 |
| Pre-Tax Profit Margin - 5YEAR AVRG. | 5.3 |
| Effective Tax Rate | 37.9 |
| Effective Tax Rate - 5YEAR AVRG. | 991.5 |
| EFFICIENCY RATIOS |
| Cash Conversion Cycle | 141 |
| Revenue per Employee | 134,435 |
| Net Income per Employee | 4,238 |
| Average Collection Period | 141 |
| Receivables Turnover | 2.6 |
| Day's Inventory Turnover Ratio | 0 |
| Inventory Turnover | 0.0 |
| Inventory/Sales | 0.0 |
| Accounts Payble/Sales | 5.11 |
| Assets/Revenue | 0.91 |
| Net Working Capital Turnover | 6.50 |
| Fixed Assets Turnover | 2.16 |
| Total Assets Turnover | 1.1 |
| Revenue per $ Cash | 12.94 |
| Revenue per $ Plant | 7.31 |
| Revenue per $ Common Equity | 3.01 |
| Revenue per $ Capital Invested | 1.88 |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 18.6 |
| SG&A Expense as % of Revenue - 5YEAR AVRG. | 18.6 |
| Research & Devlopment (R&D) as % of Revenue | 0.0 |
| R&D Expense as % of Revenue - 5YEAR AVRG. | 0.0 |
|
|  
|
| |
 |  |